Skip to Main Content
Directory of Faculty Research Interests
YSM Home

INFORMATION FOR

DownloadHi-Res Photo

Michael Cecchini, MD

Assistant Professor of Medicine (Medical Oncology); Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers; Medical Oncology Section Lead for National Accreditation Program for Rectal Cancer, Internal Medicine

Contact Information

Michael Cecchini, MD

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Dr. Cecchini focuses on developing new treatments for patients living with advanced gastrointestinal cancers. His specific research includes leveraging innovating DNA damaging therapies as a strategy to enhance the immune response. He has participated as both a principal investigator or sub-investigator on more than 100 clinical trials. This includes cooperative group studies, industry studies, as well as investigator initiated clinical trials. He is also the national principal investigator for multiple studies. In addition to his clinical research, Dr. Cecchini collaborates with multiple laboratories to perform bench to bedside research to enhance treatment options for patients living with gastrointestinal cancers.

He currently receives research funding through his NIH K08 Career Development Award which is evaluating the relationship between DNA damage and the immune response for gastrointestinal cancers. He was also awarded a Young Investigator Award from the Conquer Cancer Foundation, during his fellowship.

Coauthors

Research Interests

DNA Repair; Gastrointestinal Neoplasms; Immunotherapy

Selected Publications

Clinical Trials

ConditionsStudy Title
Phase IA Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation
Phase IOpen Label, Multicenter, Phase 1 Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 With Dose Expansion Phase, in Subjects With Advanced Solid Tumors
Phase IA Phase 1 Study of HMBD-002-V4C26 (HMBD-002), a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies
Phase IPhase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas
Phase IA Phase 1a/1b Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors
Phase IA Phase 1/2, Dose Escalation and Expansion Study of the Safety, Tolerability, and Anti-tumor Activity of BND-22 Administered Alone and in Combination With Pembrolizumab or With Cetuximab in Patients With Advanced Solid Tumors
Other Endocrine System; PancreasRandomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Colon; Esophagus; Liver; PancreasAn Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors
Phase IPhase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients With Advanced Solid Tumors (MYTHIC Study)
PancreasA Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Phase IA Phase 1/2 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Phase IPhase I, First-in-human, Open-label, Dose Escalation Trial to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of BNT152+153 in Patients With Solid Tumors
Phase IA Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination With Anti-PD-1 in Subjects With Locally Advanced or Metastatic Tumors
Phase IA Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors
Phase IA Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and anti-tumor activity of PF-07220060 as a Single Agent and as Part of Combination Therapy in Participants with Advanced Solid tumors (WIRB)
Phase IAn Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Phase IA Phase I Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Phase IA Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Liver; Lung; Melanoma, skin; Other Female GenitalPhase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial Carcinoma
Lung; StomachA Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN) Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Edit Profile